The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018.
Adjuvant
Anti-CTLA-4
Anti-PD-1
BRAF inhibitor
Immunotherapy
MEK inhibitor
Melanoma
Neoadjuvant
Targeted therapy
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
10 05 2019
10 05 2019
Historique:
received:
10
04
2019
accepted:
25
04
2019
entrez:
12
5
2019
pubmed:
12
5
2019
medline:
30
4
2020
Statut:
epublish
Résumé
The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.
Identifiants
pubmed: 31077205
doi: 10.1186/s12967-019-1892-5
pii: 10.1186/s12967-019-1892-5
pmc: PMC6509811
doi:
Substances chimiques
CTLA-4 Antigen
0
Programmed Cell Death 1 Receptor
0
Types de publication
Congress
Langues
eng
Sous-ensembles de citation
IM
Pagination
148Références
Stat Med. 1989 Apr;8(4):431-40
pubmed: 2727467
Lancet Oncol. 2014 Mar;15(3):297-304
pubmed: 24485879
BMJ. 2013 Jan 29;346:f457
pubmed: 23360719
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Nat Med. 2018 Nov;24(11):1649-1654
pubmed: 30297909
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
Lancet Oncol. 2018 Nov;19(11):1480-1492
pubmed: 30361170
N Engl J Med. 2018 Aug 23;379(8):722-730
pubmed: 30134131
Future Oncol. 2019 Feb;15(4):359-370
pubmed: 30317881
Cancer Discov. 2016 Dec;6(12):1382-1399
pubmed: 27663893
Eur J Cancer. 2017 Sep;83:247-257
pubmed: 28756137
Lancet Oncol. 2016 Jul;17(7):883-895
pubmed: 27269741
Eur J Cancer. 2017 Apr;75:47-55
pubmed: 28214657
J Clin Oncol. 2018 Oct 1;36(28):2836-2844
pubmed: 30110194
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
N Engl J Med. 2016 Nov 10;375(19):1845-1855
pubmed: 27717298
N Engl J Med. 2017 Nov 9;377(19):1813-1823
pubmed: 28891408
J Clin Oncol. 2019 Apr 10;37(11):867-875
pubmed: 30811280
Lancet Oncol. 2017 May;18(5):611-622
pubmed: 28359784
J Clin Oncol. 2017 Dec 1;35(34):3851-3858
pubmed: 28678668
J Clin Oncol. 2015 Mar 20;33(9):1008-14
pubmed: 25667291
Eur J Cancer. 2017 Sep;82:171-183
pubmed: 28692949
Biostatistics. 2000 Mar;1(1):49-67
pubmed: 12933525
J Natl Cancer Inst. 2018 Jan 1;110(1):
pubmed: 28922786
Ann Oncol. 2019 Apr 1;30(4):582-588
pubmed: 30715153
Nat Med. 2018 Nov;24(11):1655-1661
pubmed: 30297911